glp-1 receptor agonist Agonists New GLP-1 Guidelines for Type
Description
mock dosing with isotonic saline
TripleHormone-Receptor Agonist Retatrutide for Obesity a Phase 2 Trial
Equally, policy-driven studies are needed to evaluate cost-containment models, equitable access strategies, and the public health implications of widespread GLP-1RA adoption
SURPASS-AP-combo, respective clinical trial registration numbers NCT04537923, NCT04255433, NCT03861052, NCT03861039, NCT04093752) are not completed yet
PMID 31447084
